The US Food and Drug Administration has approved ‘Foundayo’ (orforglipron), a new daily oral weight-loss pill by Eli Lilly for adults struggling with obesity or related health conditions.
Unlike many existing treatments, Foundayo can be taken any time of day without food restrictions. Clinical trials showed significant weight loss compared to a placebo, though some users experienced nausea and digestive side effects.
The pill will start shipping on April 6, giving patients a simpler alternative to injectable therapies, with insurance coverage varying by provider.